These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 24887634)

  • 1. Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline.
    Gjestad C; Westin AA; Skogvoll E; Spigset O
    Ther Drug Monit; 2015 Feb; 37(1):90-7. PubMed ID: 24887634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study.
    Strawn JR; Poweleit EA; Ramsey LB
    J Child Adolesc Psychopharmacol; 2019 Jun; 29(5):340-347. PubMed ID: 30817183
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ; Andersson TB; Ahlström M; Weidolf L
    Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton pump inhibitors may enhance the risk of citalopram- and escitalopram-associated sudden cardiac death among patients receiving hemodialysis.
    Assimon MM; Pun PH; Al-Khatib SM; Brookhart MA; Gaynes BN; Winkelmayer WC; Flythe JE
    Pharmacoepidemiol Drug Saf; 2022 Jun; 31(6):670-679. PubMed ID: 35285107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of selective serotonin reuptake inhibitors.
    Hiemke C; Härtter S
    Pharmacol Ther; 2000 Jan; 85(1):11-28. PubMed ID: 10674711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
    Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
    Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
    Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
    Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A target trial emulation comparing the antidepressant effectiveness of selective serotonin reuptake inhibitors (SSRIs) highlighting the importance of patent-related confounding by indication.
    Rohde C; Hieronymus F; Østergaard SD
    Acta Psychiatr Scand; 2024 Oct; 150(4):198-208. PubMed ID: 38994727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Drug Monitoring of Selective Serotonin Reuptake Inhibitors in Elderly Patients.
    Hermann M; Waade RB; Molden E
    Ther Drug Monit; 2015 Aug; 37(4):546-9. PubMed ID: 25565671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Impact of Co-medication of Levetiracetam and Clobazam with Proton Pump Inhibitors: A Drug Interaction Study.
    Pasupuleti B; Gone V; Baddam R; Venisetty RK; Prasad OP
    Curr Drug Metab; 2020; 21(2):126-131. PubMed ID: 32067615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.
    Waade RB; Hermann M; Moe HL; Molden E
    Eur J Clin Pharmacol; 2014 Aug; 70(8):933-40. PubMed ID: 24858822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
    Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
    Abed MN; Alassaf FA; Jasim MHM; Alfahad M; Qazzaz ME
    Pharmacology; 2020; 105(11-12):645-651. PubMed ID: 32289807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation into the impact of proton pump inhibitors on sertraline transport across the blood-brain barrier.
    Xiao Y; Xu W; Niu D; Quan Z; Wang L
    Eur J Pharm Sci; 2024 Mar; 194():106653. PubMed ID: 38006986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative analysis of selective serotonin reuptake inhibitors and fall risk in older adults.
    Haddad YK; Kakara R; Marcum ZA
    J Am Geriatr Soc; 2022 May; 70(5):1450-1460. PubMed ID: 35132611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereoselective disposition of proton pump inhibitors.
    Andersson T; Weidolf L
    Clin Drug Investig; 2008; 28(5):263-79. PubMed ID: 18407713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
    Klotz U
    Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects.
    Malling D; Poulsen MN; Søgaard B
    Br J Clin Pharmacol; 2005 Sep; 60(3):287-90. PubMed ID: 16120067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine.
    Owens MJ; Knight DL; Nemeroff CB
    Biol Psychiatry; 2001 Sep; 50(5):345-50. PubMed ID: 11543737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of clinically significant interactions between concomitantly administered rasagiline and escitalopram.
    Hilli J; Korhonen T; Laine K
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1526-32. PubMed ID: 19733607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.